Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Breast Cancer Res ; 21(1): 123, 2019 11 21.
Article in English | MEDLINE | ID: mdl-31752957

ABSTRACT

BACKGROUND: Development of metastases and drug resistance are still a challenge for a successful systemic treatment in breast cancer (BC) patients. One of the mechanisms that confer metastatic properties to the cell relies in the epithelial-to-mesenchymal transition (EMT). Moreover, both EMT and metastasis are partly modulated through epigenetic mechanisms, by repression or induction of specific related genes. METHODS: We applied shRNAs and drug targeting approaches in BC cell lines and metastatic patient-derived xenograft (PDX) models to inhibit WDR5, the core subunit of histone H3 K4 methyltransferase complexes, and evaluate its role in metastasis regulation. RESULT: We report that WDR5 is crucial in regulating tumorigenesis and metastasis spreading during BC progression. In particular, WDR5 loss reduces the metastatic properties of the cells by reverting the mesenchymal phenotype of triple negative- and luminal B-derived cells, thus inducing an epithelial trait. We also suggest that this regulation is mediated by TGFß1, implying a prominent role of WDR5 in driving EMT through TGFß1 activation. Moreover, such EMT reversion can be induced by drug targeting of WDR5 as well, leading to BC cell sensitization to chemotherapy and enhancement of paclitaxel-dependent effects. CONCLUSIONS: We suggest that WDR5 inhibition could be a promising pharmacologic approach to reduce cell migration, revert EMT, and block metastasis formation in BC, thus overcoming resistance to standard treatments.


Subject(s)
Breast Neoplasms/genetics , Breast Neoplasms/pathology , Epithelial-Mesenchymal Transition/genetics , Intracellular Signaling Peptides and Proteins/genetics , Phenotype , Animals , Breast Neoplasms/drug therapy , Breast Neoplasms/metabolism , Cell Line, Tumor , Cell Proliferation , Disease Models, Animal , Disease Progression , Epithelial-Mesenchymal Transition/drug effects , Female , Gene Expression Regulation, Leukemic , Heterografts , Humans , Intracellular Signaling Peptides and Proteins/antagonists & inhibitors , Intracellular Signaling Peptides and Proteins/metabolism , Mice , Mice, Transgenic , Models, Biological , Neoplasm Metastasis , Neoplasm Staging , RNA Interference , RNA, Small Interfering/genetics , Signal Transduction , Transcription, Genetic , Transforming Growth Factor beta1/metabolism
2.
Sci Rep ; 13(1): 9287, 2023 Jun 07.
Article in English | MEDLINE | ID: mdl-37286574

ABSTRACT

Ionospheric irregularities are plasma density variations that occur at various altitudes and latitudes and whose size ranges from a few meters to a few hundred kilometers. They can have a negative impact on the Global Navigation Satellite Systems (GNSS), on their positioning accuracy and even cause a signal loss of lock (LoL), a phenomenon for which GNSS receivers can no longer track the satellites' signal. Nowadays, the study of plasma density irregularities is important because many of the crucial infrastructures of our society rely on the efficient operation of these positioning systems. It was recently discovered that, of all possible ionospheric plasma density fluctuations, those in a turbulent state and characterized by extremely high values of the Rate Of change of the electron Density Index appear to be associated with the occurrence of LoL events. The spatial distributions of this class of fluctuations at mid and high latitudes are reconstructed for the first time using data collected on Swarm satellites between July 15th, 2014 and December 31st, 2021, emphasizing their dependence on solar activity, geomagnetic conditions, and season. The results unequivocally show that the identified class of plasma fluctuations exhibits spatio-temporal behaviours similar to those of LoL events.

3.
J Invest Dermatol ; 143(10): 1993-2006.e10, 2023 10.
Article in English | MEDLINE | ID: mdl-37003468

ABSTRACT

Despite the remarkable improvements achieved in the management of metastatic melanoma, there are still unmet clinical needs. A considerable fraction of patients does not respond to immune and/or targeted therapies owing to primary and acquired resistance, high-grade immune-related adverse events, and a lack of alternative treatment options. To design effective combination therapies, we set up a functional ex vivo preclinical assay on the basis of a drop-out genetic screen in metastatic melanoma patient-derived xenografts. We showed that this approach can be used to isolate actionable vulnerabilities predictive of drug efficacy. In particular, we highlighted that the dual targeting of AURKA and MAPK/extracellular signal-regulated kinase kinase employing the combination of alisertib and trametinib is highly effective in a cohort of metastatic melanoma patient-derived xenografts, both ex vivo and in vivo. Alisertib and trametinib combination therapy outperforms standard-of-care therapy in both BRAF-mutant patient-derived xenografts and targeted therapy-resistant models. Furthermore, alisertib and trametinib treatment modulates several critical cancer pathways, including an early metabolic reprogramming that leads to the transcriptional upregulation of the fatty acid oxidation pathway. This acquired trait unveiled an additional point of intervention for pharmacological targeting, and indeed, the triple combination of alisertib and trametinib with the fatty acid oxidation inhibitor etomoxir proved to be further beneficial, inducing tumor regression and remarkably prolonging the overall survival of the mice.


Subject(s)
Aurora Kinase A , Melanoma , Humans , Mice , Animals , Aurora Kinase A/genetics , Protein Kinase Inhibitors/pharmacology , Protein Kinase Inhibitors/therapeutic use , Melanoma/drug therapy , Melanoma/genetics , Pyrimidinones/therapeutic use , Mitogen-Activated Protein Kinase Kinases , Fatty Acids , Proto-Oncogene Proteins B-raf/genetics , Mutation
4.
Life Sci Alliance ; 2(1)2019 02.
Article in English | MEDLINE | ID: mdl-30760554

ABSTRACT

Inflammatory bowel disease (IBD) pathogenesis has been linked to the aberrant activation of the Gut-associated lymphoid tissues against components of the intestinal microbiota. Although the contribution of CD4+ T helper cells to inflammatory processes is being increasingly acknowledged, the functional engagement of human invariant natural killer T (iNKT) cells is still poorly defined. Here, we evaluated the functional characteristics of intestinal iNKT cells during IBD pathogenesis and to exploit the role of mucosa-associated microbiota recognition in triggering iNKT cells' pro-inflammatory responses in vivo. Lamina propria iNKT cells, isolated from surgical specimens of active ulcerative colitis and Crohn's disease patients and non-IBD donors, were phenotypically and functionally analyzed ex vivo, and stable cell lines and clones were generated for in vitro functional assays. iNKT cells expressing a pro-inflammatory cytokine profile were enriched in the lamina propria of IBD patients, and their exposure to the mucosa-associated microbiota drives pro-inflammatory activation, inducing direct pathogenic activities against the epithelial barrier integrity. These observations suggest that iNKT cell pro-inflammatory functions may contribute to the fuelling of intestinal inflammation in IBD patients.


Subject(s)
Colitis, Ulcerative/microbiology , Crohn Disease/microbiology , Gastrointestinal Microbiome , Intestinal Mucosa/microbiology , Natural Killer T-Cells/metabolism , Adult , Aged , Aged, 80 and over , Animals , CD4 Antigens/metabolism , Caco-2 Cells , Clone Cells/metabolism , Coculture Techniques , Colitis, Ulcerative/chemically induced , Colitis, Ulcerative/pathology , Colitis, Ulcerative/surgery , Crohn Disease/surgery , Cytokines/metabolism , Dextran Sulfate/pharmacology , Disease Models, Animal , Female , Humans , Inflammation/immunology , Inflammation/metabolism , Intestinal Mucosa/immunology , Lymphocyte Activation/immunology , Male , Mice , Mice, Inbred C57BL , Middle Aged , NK Cell Lectin-Like Receptor Subfamily B/metabolism , Natural Killer T-Cells/immunology , Phenotype
5.
J Crohns Colitis ; 12(8): 981-992, 2018 Jul 30.
Article in English | MEDLINE | ID: mdl-29697763

ABSTRACT

BACKGROUND AND AIMS: T helper 17 [Th17] cells are crucially involved in the immunopathogenesis of inflammatory bowel diseases in humans. Nevertheless, pharmacological blockade of interleukin 17A [IL17A], the Th17 signature cytokine, yielded negative results in patients with Crohn's disease [CD], and attempts to elucidate the determinants of Th17 cells' pathogenicity in the gut have so far proved unsuccessful. Here, we aimed to identify and functionally validate the pathogenic determinants of intestinal IL-17-producing T cells. METHODS: In vivo-generated murine intestinal IL-17-producing T cells were adoptively transferred into immunodeficient Rag1-/- recipients to test their pathogenicity. Human IL-17, IFNγ/IL-17, and IFNγ actively secreting T cell clones were generated from lamina propria lymphocytes of CD patients. The pathogenic activity of intestinal IL-17-producing T cells against the intestinal epithelium was evaluated. RESULTS: IL-17-producing cells with variable colitogenic activity can be generated in vivo using different experimental colitis models. The pathogenicity of IL-17-secreting cells was directly dependent on their IFNγ secretion capacity, as demonstrated by the reduced colitogenic activity of IL-17-secreting cells isolated from IFNγ-/- mice. Moreover, IFNγ production is a distinguished attribute of CD-derived lamina propria Th17 cells. IFNγ secretion by CD-derived IL-17-producing intestinal clones is directly implicated in the epithelial barrier disruption through the modulation of tight junction proteins. CONCLUSIONS: Intestinal Th17 cell pathogenicity is associated with IFNγ production, which directly affects intestinal permeability through the disruption of epithelial tight junctions.


Subject(s)
Colitis/immunology , Crohn Disease/pathology , Interferon-gamma/metabolism , Intestinal Mucosa/pathology , Th17 Cells/immunology , Th17 Cells/metabolism , Adult , Aged , Animals , Clone Cells/immunology , Clone Cells/metabolism , Crohn Disease/immunology , Crohn Disease/metabolism , Female , Homeodomain Proteins/genetics , Humans , Interferon-gamma/genetics , Interleukin-17/metabolism , Intestinal Mucosa/immunology , Intestinal Mucosa/metabolism , Male , Mice , Mice, Knockout , Middle Aged , Permeability , Th1 Cells/metabolism , Tight Junctions/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL